
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).






